<div>
  <ul>
    <li>
      <p>
        AI drug development company Generate Biomedicines has raised USD 273 million in a Series C funding round led by Amgen, with participation from NVentures, MAPS Capital, Pictet Alternative Advisors, and other existing investors. This brings the total fund raised by the company to USD 693 million.
      </p>
    </li>
    <li>
      <p>
        The funds will support the advancement of the company&rsquo;s pipeline of protein therapies, enhance its generative biology platform, pursue collaborations, and invest in new program starts. The company plans to file a Clinical Trial Application for its anti-TSLP monoclonal antibody by early Q4 2023 and initiate multiple clinical trials annually. In addition, Generate Biomedicines also aims to submit multiple Investigational New Drug (IND) applications in 2024.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://generatebiomedicines.com/news/series-c-financing-announcement">
      Press release
    </a>
  </p>
  <p>
    <a href="https://ts2.space/en/generatebiomedicines-raises-273m-in-series-c-funding-to-advance-ai-driven-drug-discovery/">
      TS2
    </a>
  </p>
  <p>
  </p>
</div>


AI Drug Discovery

Generate Biomedicines, an AI drug development company, has secured $273 million in a Series C funding round led by Amgen, with participation from several investors. The company's total funding now stands at $693 million. These funds will be used to advance the company's pipeline of protein therapies, improve its generative biology platform, enter into collaborations, and invest in new programs. Generate Biomedicines plans to file a Clinical Trial Application for its anti-TSLP monoclonal antibody in Q4 2023 and initiate multiple clinical trials annually, as well as submit multiple Investigational New Drug applications in 2024.

Generate Biomedicines raises USD 273 million in Series C funding

Novel therapies to reboot cells and organs

Cell & Gene Therapy

Generate Biomedicines, an AI drug development company, has raised $273 million in a Series C funding round. The funding, led by Amgen, brings the total amount raised by the company to $693 million. The funds will be used to support the company's pipeline of protein therapies, enhance its generative biology platform, collaborate with other entities, and invest in new program starts. Generate Biomedicines plans to file a Clinical Trial Application for its anti-TSLP monoclonal antibody by early Q4 2023 and initiate multiple clinical trials annually. Additionally, the company aims to submit multiple Investigational New Drug applications in 2024.

All Updates

Generate Biomedicines raises USD 273 million in Series C funding

Generate Biomedicines raises USD 273 million in Series C funding

Generate Biomedicines and Amgen enter into USD 1.9 billion research collaboration

Generate Biomedicines raises USD 370 million Series B